Literature DB >> 28688290

The efficacy of plant extract and bioactive compounds approaches in the treatment of pulmonary fibrosis: A systematic review.

Sana Bahri1, Ridha Ben Ali2, Anouar Abidi3, Saloua Jameleddine3.   

Abstract

Pulmonary fibrosis (PF) is a lethal, chronic and progressive respiratory disease leading to interstitial lung damage and serious breathing problems. The pathogenic mechanism involves activation, migration, proliferation and differentiation of fibroblasts into myofibroblats inducing extracellular matrix accumulation that destroy lung parenchyma. Available antifibrotic treatment options are limited to Pirfenidone and Nintedanib that prevent deterioration without an improvement of this disease. The use of plant extracts and natural bioactive compounds for the treatment of PF has been known for more than thirty years in China. Nowadays, phytotherapy has gained a considerable attention in the treatment of PF both in vivo and in vitro using bleomycin (BLM)-induced lung inflammation, oxidative stress and pulmonary fibrosis in rats. In this review, we aimed to focus on the protective effects and the mechanisms of action of several plant extracts described by various research works for the treatment of PF.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bioactive compounds; Plant extract; Pulmonary fibrosis

Mesh:

Substances:

Year:  2017        PMID: 28688290     DOI: 10.1016/j.biopha.2017.06.052

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Modeling Kaempferol as a Potential Pharmacological Agent for COVID-19/PF Co-Occurrence Based on Bioinformatics and System Pharmacological Tools.

Authors:  Yong Jiang; Yi-Zi Xie; Chen-Wen Peng; Kai-Nan Yao; Xue-Ying Lin; Shao-Feng Zhan; Hong-Fa Zhuang; Hui-Ting Huang; Xiao-Hong Liu; Xiu-Fang Huang; Hang Li
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

2.  The efficacy and safety of pinocembrin in a sheep model of bleomycin-induced pulmonary fibrosis.

Authors:  Habtamu B Derseh; Jason Q D Goodger; Jean-Pierre Y Scheerlinck; Chrishan S Samuel; Ian E Woodrow; Enzo A Palombo; Alistair Cumming; Ken Snibson
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

3.  Cyanidin-3-galactoside from Aronia melanocarpa ameliorates silica-induced pulmonary fibrosis by modulating the TGF-β/mTOR and NRF2/HO-1 pathways.

Authors:  Yanmin Cui; Jin Zhao; Jing Chen; Yanwen Kong; Mingyue Wang; Yan Ma; Xianjun Meng
Journal:  Food Sci Nutr       Date:  2022-03-30       Impact factor: 3.553

4.  Cymbopogon winterianus Essential Oil Attenuates Bleomycin-Induced Pulmonary Fibrosis in a Murine Model.

Authors:  Lívia A Tavares; Allan A Rezende; Jymmys L Santos; Charles S Estevam; Ana M O Silva; Jaderson K Schneider; John L S Cunha; Daniela Droppa-Almeida; Ivan J Correia-Neto; Juliana C Cardoso; Patricia Severino; Eliana B Souto; Ricardo L C de Albuquerque-Júnior
Journal:  Pharmaceutics       Date:  2021-05-09       Impact factor: 6.321

Review 5.  Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments.

Authors:  Palanivel Ganesan; Govindarajan Karthivashan; Shin Young Park; Joonsoo Kim; Dong-Kug Choi
Journal:  Int J Nanomedicine       Date:  2018-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.